Literature DB >> 1596563

"Stem cell" origin of the hematopoietic defect in dyskeratosis congenita.

J C Marsh1, A J Will, J M Hows, P Sartori, P J Darbyshire, P J Williamson, D G Oscier, T M Dexter, N G Testa.   

Abstract

We have used the long-term bone marrow culture (LTBMC) system to analyze hematopoiesis in three patients with dyskeratosis congenita (DC), two of whom had aplastic anemia, and the third had a normal blood count (apart from mild macrocytosis) and normal BM cellularity. Hematopoiesis was severely defective in all three patients, as measured by a low incidence of colony-forming cells and a low level of hematopoiesis in LTBMC. The function of the marrow stroma was normal in its ability to support the growth of hematopoietic progenitors from normal marrows seeded onto them in all three cases, but the generation of hematopoietic progenitors from patients marrow cells inoculated onto normal stromas was reduced, thus suggesting the defect to be of stem cell origin. The parents and unaffected brother of one of the families have also been studied in LTBMC and all showed normal hematopoietic and stromal cell function. From this study we speculate that there are some similarities between DC and the defect in the W/Wv mouse.

Entities:  

Mesh:

Year:  1992        PMID: 1596563

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Skewed X-chromosome inactivation in female carriers of dyskeratosis congenita.

Authors:  K Devriendt; G Matthijs; E Legius; E Schollen; D Blockmans; C van Geet; H Degreef; J J Cassiman; J P Fryns
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

2.  Nonrandom X-chromosome inactivation in hemopoietic cells from carriers of dyskeratosis congenita.

Authors:  A M Ferraris; G L Forni; R Mangerini; G F Gaetani
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

Review 3.  RNA-guided isomerization of uridine to pseudouridine--pseudouridylation.

Authors:  Yi-Tao Yu; U Thomas Meier
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

4.  Treatment of the hematological manifestations of dyskeratosis congenita.

Authors:  C Putterman; R Safadi; J Zlotogora; R Banura; A Eldor
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

Review 5.  Dyskeratosis congenita, stem cells and telomeres.

Authors:  Michael Kirwan; Inderjeet Dokal
Journal:  Biochim Biophys Acta       Date:  2009-02-07

Review 6.  Cancer in dyskeratosis congenita.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; Philip S Rosenberg
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

Review 7.  Advances in the understanding of dyskeratosis congenita.

Authors:  Amanda J Walne; Inderjeet Dokal
Journal:  Br J Haematol       Date:  2009-02-04       Impact factor: 6.998

8.  Effective stimulation of neutropoiesis with rh G-CSF in dyskeratosis congenita: a case report.

Authors:  L Oehler; E Reiter; J Friedl; E Kabrna; O A Haas; A Rosenkranz; K Lechner; K Geissler
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

9.  Red blood cell size is inversely associated with leukocyte telomere length in a large multi-ethnic population.

Authors:  Julia Kozlitina; Christine Kim Garcia
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240

Review 10.  Cellular differences in protein synthesis regulate tissue homeostasis.

Authors:  Michael Buszczak; Robert A J Signer; Sean J Morrison
Journal:  Cell       Date:  2014-10-09       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.